Sunita Dwivedy Nasta
Overview
Explore the profile of Sunita Dwivedy Nasta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikiforow S, Whangbo J, Reshef R, Tsai D, Bunin N, Abu-Arja R, et al.
Blood Adv
. 2024 Apr;
8(12):3001-3012.
PMID: 38625984
Patients with Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (EBV+ PTLD) in whom initial treatment fails have few options and historically low median overall survival (OS) of 0.7 months after allogeneic...
2.
Svoboda J, Bair S, Landsburg D, Nasta S, Nagle S, Barta S, et al.
Haematologica
. 2020 May;
106(6):1705-1713.
PMID: 32414850
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+)...
3.
Rhodes J, LoRe 3rd V, Mato A, Chong E, Barrientos J, Gerson J, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Mar;
20(7):438-444.e1.
PMID: 32197990
Introduction: The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has transformed the treatment of chronic lymphocytic leukemia (CLL), leading to unprecedented improvements in progression-free and overall survival for all patients, including...
4.
Rhodes J, Schuster S, Furth E, Kennard K, Nasta S, Svoboda J, et al.
Cancer Biol Ther
. 2019 May;
20(8):1136-1140.
PMID: 31091174
Giant cell hepatitis (GCH) is a rare diagnosis in adults that is found in 0.25% of liver biopsies. GCH has been associated with multiple causes including drugs (6-mercaptopurine, methotrexate), toxins,...
5.
Farhan A, Chong E, Schuster S, Strelec L, Nasta S, Landsburg D, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Nov;
19(2):109-115.
PMID: 30448048
Background: Peripheral T-cell lymphomas (PTCLs) are generally aggressive non-Hodgkin lymphomas that portend poor prognosis with currently available therapies. Bexarotene, a retinoic acid derivative, has efficacy in cutaneous T-cell lymphomas, but...
6.
Cherng H, Sargent R, Nasta S, Svoboda J, Schuster S, Mato A, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Jul;
18(10):673-678.
PMID: 30033208
Background: Patients with a diagnosis of MYC-rearranged non-Burkitt aggressive B-cell lymphoma (MYC-R), including those with double hit lymphoma, are at high risk of developing relapsed/refractory disease, even if treated with...
7.
Svoboda J, Rheingold S, Gill S, Grupp S, Lacey S, Kulikovskaya I, et al.
Blood
. 2018 Jun;
132(10):1022-1026.
PMID: 29925499
Chimeric antigen receptor (CAR)-modified T cells are being investigated in many settings, including classical Hodgkin lymphoma (cHL). The unique biology of cHL, characterized by scant Hodgkin and Reed-Sternberg (HRS) cells...
8.
Mato A, Nabhan C, Barr P, Ujjani C, Hill B, Lamanna N, et al.
Blood
. 2016 Sep;
128(18):2199-2205.
PMID: 27601462
B-cell receptor kinase inhibitor (KI) therapy represents a paradigm shift in chronic lymphocytic leukemia (CLL) management, but data on practice patterns after KI discontinuation and optimal sequencing are limited. We...
9.
Howlett C, Snedecor S, Landsburg D, Svoboda J, Chong E, Schuster S, et al.
Br J Haematol
. 2015 Apr;
170(4):504-14.
PMID: 25907897
'Double-hit lymphomas' (DHL), defined by concurrent MYC and BCL2 (or, alternatively, BCL6) rearrangements, have a very poor outcome compared to standard-risk, diffuse large B-cell lymphomas (DLBCL). Consequently, dose-intensive (DI) therapies...
10.
Nasta S, Hoff P, George C, Neubauer M, Cohen S, Abbruzzese J, et al.
Am J Clin Oncol
. 2003 Apr;
26(2):132-4.
PMID: 12714882
We examined the use of MGI-114 (6-hydroxymethyacylfulvene) for the treatment of patients with advanced colorectal carcinoma. Twenty-six patients were enrolled, with a median age of 60 years (range 41-75); 64%...